title: Influence of moxifloxacin, comparator drugs and some fractions of pulmonary surfactant on adherence of some respiratory pathogens.
abstract: BACKGROUND
  This study evaluated the effect of moxifloxacin and comparator drugs with or without some fractions of pulmonary surfactant, as surfactant protein-A (SP-A) and phospholipids, on the adherence of the most common respiratory pathogens.
  
  
  METHODS
  The adherence of respiratory pathogens to a bronchial epithelial cell line was tested. Antimicrobials were used at 1/2, 1/4 and 1/8 minimum inhibitory concentration (MIC), SP-A at 1 and 5 microg/ml and phospholipids at 50 microg/ml.
  
  
  RESULTS
  At 1/2 MIC moxifloxacin, ciprofloxacin, amoxicillin-clavulanate and ceftriaxone reduced the adherence of Staphylococcus aureus and Streptococcus pneumoniae to values of 40-50%. At the same concentration, cotrimoxazole reduced the adherence values of Moraxella catarrhalis and Haemophilus influenzae to about 50%, while beta-lactams showed high efficacy only on H. influenzae, with adherence values of about 40%. The addition of SP-A and/or phospholipids to the tested antibiotics had no effect on bacterial adherence.
  
  
  CONCLUSIONS
  The non-interference of SP-A and/or phospholipids with the suppressive effect that some antibiotics exert on bacterial adherence could represent a favorable event during antibiotic therapy.
authors.forename: A
authors.initials: A
authors.lastname: Ferrara
authors.forename: C
authors.initials: C
authors.lastname: Dos Santos
authors.forename: M T
authors.initials: MT
authors.lastname: Tellarini
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D002448:Cell Adhesion / Q000187:drug effects*; D002460:Cell Line; D004347:Drug Interactions; D004847:Epithelial Cells / Q000187:drug effects / Q000502:physiology; D024841:Fluoroquinolones; D006193:Haemophilus influenzae / Q000187:drug effects / Q000502:physiology; D006801:Humans; D008168:Lung / Q000166:cytology; D001936:Moraxella catarrhalis / Q000187:drug effects / Q000502:physiology; D000077266:Moxifloxacin; D010743:Phospholipids / Q000494:pharmacology; D037662:Pulmonary Surfactant-Associated Protein A / Q000494:pharmacology*; D011663:Pulmonary Surfactants / Q000494:pharmacology*; D011804:Quinolines; D013211:Staphylococcus aureus / Q000187:drug effects / Q000502:physiology; D013296:Streptococcus pneumoniae / Q000187:drug effects / Q000502:physiology
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D010743:Phospholipids; D037662:Pulmonary Surfactant-Associated Protein A; D011663:Pulmonary Surfactants; D011804:Quinolines; D000077266:Moxifloxacin